Explore

Trendline Trendline
Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies

Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies

Bicycle Therapeutics Reports Q1 2026 Financial Results, Highlights Progress in Cancer Therapies
Trendline Trendline
Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026

Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026

Bicycle Therapeutics Reports Strategic Reprioritization and Financial Results for Q1 2026
Trendline Trendline
D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types

D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types

D3 Bio's KRAS G12C Inhibitor Shows Promising Phase 2 Results Across Multiple Tumor Types
Trendline Trendline
Pfizer's ELREXFIO Shows Promising Results in Multiple Myeloma Treatment

Pfizer's ELREXFIO Shows Promising Results in Multiple Myeloma Treatment

Pfizer's ELREXFIO Shows Promising Results in Multiple Myeloma Treatment
Trendline Trendline
Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

Summit Therapeutics Reports Q1 2026 Financial Results and Clinical Progress
Trendline Trendline
D3 Bio's KRAS Inhibitor Shows Promising Results in Phase 2 Trials for Multiple Tumors

D3 Bio's KRAS Inhibitor Shows Promising Results in Phase 2 Trials for Multiple Tumors

D3 Bio's KRAS Inhibitor Shows Promising Results in Phase 2 Trials for Multiple Tumors
Trendline Trendline
Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma

Pfizer's ELREXFIO Shows Promise in Treating Relapsed Multiple Myeloma
Trendline Trendline
Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology

Merck Discontinues Early-Stage TROP ADC Amid Strategic Shifts in Oncology
Trendline Trendline
Janux Therapeutics Halts Development of JANX008 Due to Insufficient Clinical Activity

Janux Therapeutics Halts Development of JANX008 Due to Insufficient Clinical Activity

Janux Therapeutics Halts Development of JANX008 Due to Insufficient Clinical Activity
Trendline Trendline
Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment

Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment

Moderna's mRNA-4359 and Merck's Keytruda Show Promising Results in Melanoma Treatment
Trendline Trendline
Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026

Moderna and Marengo Present Promising Cancer Combo Therapies at AACR 2026
Trendline Trendline
FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma

FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma

FDA Approves Taiho Oncology's ADC ARC-02 for Phase 1 Clinical Trials in Non-Hodgkin Lymphoma